Boehringer And Anthem Put Stiolto Duo To Real World Test In COPD
Executive Summary
US noninferiority study mainly of Anthem beneficiaries aims to show if COPD patients are being overtreated with LABA/LAMA/ICS triple combos when a LABA/LAMA duo would do.
You may also be interested in...
GOLD Pushes LABA/LAMA Class In New COPD Treatment Update
New guidelines for the treatment of COPD could change the way this serious condition is managed, with knock-on effects for pharma companies with respiratory franchises.
Real-World Evidence: Lessons From GSK's Salford Lung Study
The Salford Lung Study is pioneering in the emerging field of gathering real-world evidence. David Leather, Global Medical Affairs Leader in the Respiratory Franchise at GSK, led the UK-based study and talked to the Pink Sheet about why it was important for GSK and what may come next.
Boehringer/WellPoint Outcomes Research To Inform Pradaxa Treatment
The study in non-valvular atrial fibrillation patients is the first project to launch under a five-year research agreement between Boehringer Ingelheim and WellPoint.